Company Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.

The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.

Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Oramed Pharmaceuticals Inc.

Country	United States
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Nadav Kidron

Contact Details

Address: 1185 Avenue of the Americas, Third Floor New York, New York 10036 United States
Phone	844 967 2633
Website	oramed.com

Stock Details

Ticker Symbol	ORMP
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001176309
CUSIP Number	68403P203
ISIN Number	US68403P2039
Employer ID	98-0376008
SIC Code	2834

Key Executives

Name	Position
Nadav Kidron Esq.	President, Chief Executive Officer and Executive Chairman
Avraham Gabay	Chief Financial Officer, Treasurer and Secretary
Joshua Hexter	Chief Operating and Business Officer
Dr. Miriam Kidron Ph.D.	Chief Scientific Officer and Director

Latest SEC Filings

Date	Type	Title
Nov 17, 2025	8-K	Current Report
Nov 17, 2025	8-A12B	Registration of securities
Nov 17, 2025	8-K	Current Report
Nov 13, 2025	10-Q	Quarterly Report
Oct 24, 2025	8-K	Current Report
Oct 6, 2025	8-K	Current Report
Aug 28, 2025	SCHEDULE 13D/A	Filing
Aug 21, 2025	S-8	Securities to be offered to employees in employee benefit plans
Aug 21, 2025	8-K	Current Report
Aug 14, 2025	10-Q	Quarterly Report

View All SEC Filings